Polymerase + Protease Inhibitor: Two Good Can Become the Best
Pharmasset (VRUS) has created immense value for its shareholders by promising the best treatment options in HCV on its own or through collaborations. The latest collaboration with Tibotec/J&J/Medivir is another step in the right direction. For more details on the value additions and HCV market dynamic please read our note released on 7th July on Pharmasset and Medivir titled “Monetizing Polymerase + Protease Inhibitor: Two Good Can Become the Best”. With this report you will also receive the Initiation report on Medivir and detailed report on VRUS absolutely free. A discounted offer for a comprehensive therapy class report with market model of the drugs for treating HCV infection is valid with this purchase!
COMPANIES MENTIONED
PHARMASSET, MEDIVIR AB
PHARMASSET, MEDIVIR AB
More Publications
Hepatitis C Virus Infection: Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?
US$ 2,000.00
April 2012
57 pages
Medivir AB – Initiating as an Outperform - Next in HCV- A Once Daily Protease Inhibitor Option
US$ 140.00
June 2011
6 pages
